U.S. markets closed
  • S&P 500

    4,163.26
    -22.21 (-0.53%)
     
  • Dow 30

    34,077.63
    -123.04 (-0.36%)
     
  • Nasdaq

    13,914.77
    -137.58 (-0.98%)
     
  • Russell 2000

    2,232.00
    -30.67 (-1.36%)
     
  • Crude Oil

    63.56
    +0.18 (+0.28%)
     
  • Gold

    1,771.00
    +0.40 (+0.02%)
     
  • Silver

    25.84
    +0.00 (+0.01%)
     
  • EUR/USD

    1.2042
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6010
    +0.0280 (+1.78%)
     
  • GBP/USD

    1.3991
    +0.0007 (+0.05%)
     
  • USD/JPY

    108.1020
    -0.0480 (-0.04%)
     
  • BTC-USD

    55,652.60
    -775.74 (-1.37%)
     
  • CMC Crypto 200

    1,273.66
    -25.30 (-1.95%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.

Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 90 days.

About Savara
Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Apulmiq is an inhaled ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savara’s strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20200909006024/en/

Contacts

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366